The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Babaeva N.A.

Federal State Institution «Research Center for Obstetrics, Gynecology and Perinatology» Ministry of Healthcare of Russian Federation

Yureneva S.V.

Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology

Aleshikova O.I.

Federal State Institution «Research Center for Obstetrics, Gynecology and Perinatology» Ministry of Healthcare of Russian Federation

Yakushevskaya O.V.

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology Ministry of Health of the Russian Federation

Ashraphyan L.A.

Federal State Institution «Research Center for Obstetrics, Gynecology and Perinatology» Ministry of Healthcare of Russian Federation

Possibilities of using hormone therapy in patients treated for malignant neoplasms of the vulva, vagina, and uterine cervix and body

Authors:

Babaeva N.A., Yureneva S.V., Aleshikova O.I., Yakushevskaya O.V., Ashraphyan L.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2023;12(1): 45‑52

DOI: 10.17116/onkolog20231201145

Read: 5260 times

Download PDF (RU)
Contact the author
Table of contents

POSSIBILITIES OF USING HORMONE THERAPY IN PATIENTS TREATED FOR MALIGNANT NEOPLASMS OF THE VULVA, VAGINA, AND UTERINE CERVIX AND BODY
POSSIBILITIES OF USING HORMONE THERAPY IN PATIENTS TREATED FOR MALIGNANT NEOPLASMS OF THE VULVA, VAGINA, AND UTERINE CERVIX AND BODY

To cite this article:

Babaeva NA, Yureneva SV, Aleshikova OI, Yakushevskaya OV, Ashraphyan LA. Possibilities of using hormone therapy in patients treated for malignant neoplasms of the vulva, vagina, and uterine cervix and body. P.A. Herzen Journal of Oncology. 2023;12(1):45‑52. (In Russ.)
https://doi.org/10.17116/onkolog20231201145

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Preoperative indi­ces of systemic inflammatory response as predictors of the presence of regional meta­stases in cervical cancer. (A systematic review and meta-analysis). P.A. Herzen Journal of Onco­logy. 2025;(6):94-102
Live birth rates after conservative treatment of atypical hype­rplasia and initial endo­metrial cancer. Russian Journal of Human Reproduction. 2025;(1):78-85
On the issue of the effe­ctiveness of HPV testing and cyto­logical examination in the framework of the combined cervical cancer screening. Russian Journal of Preventive Medi­cine. 2025;(4):23-29
Asse­ssment of the effect of meno­pause symptoms on women’s quality of life and their atti­tude to the mani­festations of meno­pause and meno­pausal hormone therapy. Russian Journal of Human Reproduction. 2025;(3):84-91
Use of gona­dotropic releasing hormone agonists in hype­rplastic syndrome in gyne­cology. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):51-58
Characteristics of the immune microenvironment of endo­metrial cancer depe­nding on the MMR status of the tumor. Russian Journal of Archive of Pathology. 2025;(5):11-19
Predictive immu­notherapeutic markers of adenocarcinomas and adenosquamous carcinoma of the cervix. Russian Journal of Archive of Pathology. 2025;(5):74-79
Modern treatment of patients with cervical cancer. Russian Bulletin of Obstetrician-Gynecologist. 2025;(6):29-36
Hete­rogeneity of mismatch repair protein expression in tumors. Russian Journal of Archive of Pathology. 2026;(1):73-79
Abstract:

The paper analyzes the data available in the literature on the possibilities of using menopausal hormone therapy (MHT) in patients who have previously been treated for cancers in the reproductive system and on the impact of hormone therapy on overall and relapse-free survivals in patients treated for malignant diseases of the vulva, vagina, and uterine cervix and body. The literature review includes the data of foreign and Russian scientists, which have been published in PubMed on this topic over the past 10 years. The authors analyze the possibilities of using MHT in women with various malignant neoplasms and determine the acceptability of using hormone therapy in patients with a history of squamous cell carcinoma of the cervix, vagina, vulva, and stage I endometrioid adenocarcinoma of the uterine body with a low risk for disease progression.

Keywords:

cervical cancer
vulvar cancer
vaginal cancer
endometrial cancer
uterine sarcomas
menopausal hormone therapy
cancer risks

Authors:

Babaeva N.A.

Federal State Institution «Research Center for Obstetrics, Gynecology and Perinatology» Ministry of Healthcare of Russian Federation

Yureneva S.V.

Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology

Aleshikova O.I.

Federal State Institution «Research Center for Obstetrics, Gynecology and Perinatology» Ministry of Healthcare of Russian Federation

Yakushevskaya O.V.

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology Ministry of Health of the Russian Federation

Ashraphyan L.A.

Federal State Institution «Research Center for Obstetrics, Gynecology and Perinatology» Ministry of Healthcare of Russian Federation

Received:

12.07.2022

Accepted:

11.08.2022

Close metadata

References:

  1. Ashrafyan LA, Balan VE, Baranov II, Belaya ZhE, Bobrov SA, Vorontsova AV, Dubrovina SO, Zazerskaya IE, Ilovaiskaya IA, Karakhalis LJu, Lesnyak OM, Mazitova MI, Podzolkova NM, Protasova AE, Serov VN, Smetnik AA, Sotnikova LS, Ul’rikh EA, Chernukha GE, Yureneva SV. Algorithmy primeneniya menopauzal’noi gormonal’noi terapii u zhenshchin v period peri- i postmenopauzy. Sovmestnaya pozitsiya ekspertov ROAG, RAM, AGE, RAOP. Akusherstvo i ginekologiya. 2021;(3):210-221. (In Russ.). https://doi.org/10.18565/aig.2021.3.210-221
  2. Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer.2006;16(2):805-808. 
  3. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(4):587-592.  https://doi.org/10.1200/JCO.2005.02.8464
  4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBACAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.  https://doi.org/10.3322/caac.21660
  5. Panay N, Anderson RA, Nappi RE, Vincent AJ, Vujovic S, Webber L, Wolfman W. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426-446.  https://doi.org/10.1080/13697137.2020.1804547
  6. Hirschberg AL, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Goulis DG, Kiesel L, Lopes P, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide. Maturitas. 2021;148:55-61.  https://doi.org/10.1016/j.maturitas.2021.04.005
  7. Weidlinger S, Schmutz C, Janka H, Gruetter C, Stute P. Sustainability of vaginal estrogens for genitourinary syndrome of menopause — a systematic review. Climacteric. 2021;24(6):551-559.  https://doi.org/10.1080/13697137.2021.1891218
  8. Prokop’eva TA. Zamestitel’naya gormonal’naya terapiya v programme rannei reabilitatsii bol’nykh posle radikal’nogo lecheniya raka sheiki matki. Sibirskii onkologicheskii zhurnal. 2002;(3-4):81-82. (In Russ.).
  9. Urmancheeva AF, Mikhailyuk GI, Ul’rikh EA. Zamestitel’naya gormonal’naya terapiya v reabilitatsii bol’nykh rakom endometriya posle radikal’nogo lecheniya. Zhurnal akusherstva i zhenskikh boleznei. 2004;53(4):53-58. (In Russ.).
  10. Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors — review of the literature. Pathol Oncol Res. 2020;26(1):63-78.  https://doi.org/10.1007/s12253-018-00569-x
  11. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018;5(5):CD008830. https://doi.org/10.1002/14651858.CD008830.pub3
  12. The National Institute for Health and Care Excellence. NICE guideline [NG23]. Menopause: diagnosis and management. 2015. https://www.nice.org.uk/guidance/ng23
  13. de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C, Pierroz DD. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016;91:153-155.  https://doi.org/10.1016/j.maturitas.2016.06.001
  14. Armeni E, Lambrinoudaki I, Ceausu I, Depypere H, Mueck A, Pérez-López FR, Schouw YT, Senturk LM, Simoncini T, Stevenson JC, et al. Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS). Maturitas. 2016;89:63-72.  https://doi.org/10.1016/j.maturitas.2016.04.013
  15. Shifren JL, Gass MLS; NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038-1062. https://doi.org/10.1097/GME.0000000000000319
  16. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause — 2017 update. Endocr Pract. 2017;23(7):869-880.  https://doi.org/10.4158/EP171828.PS
  17. Pickar JH, Boucher M, Morgenstern D. Tissue selective estrogen complex (TSEC): a review. Menopause. 2018;25(9):1033-1045. https://doi.org/10.1097/GME.0000000000001095
  18. Di Donato V, Schiavi MC, Iacobelli V, D’oria O, Kontopantelis E, Simoncini T, Muzii L, Benedetti Panici P. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety. Maturitas. 2019;121:93-100.  https://doi.org/10.1016/j.maturitas.2018.11.017
  19. Sauer U, Talaulikar V, Davies MC. Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase. Maturitas. 2018;116:79-82.  https://doi.org/10.1016/j.maturitas.2018.07.016
  20. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2020. M.: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radioologii» Ministerstva zdravookhraneniya Rossiiskoi Federatsii; 2021;239. (In Russ.).
  21. Lacey JV Jr, Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, McGoan LM, Mortel R, Schwartz PE, Kurman RJ, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol. 2000;77(1):149-154.  https://doi.org/10.1006/gyno.2000.5731
  22. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol. 1987;26(2):169-177.  https://doi.org/10.1016/0090-8258(87)90270-8
  23. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 1989;44(5):833-839.  https://doi.org/10.1002/ijc.2910440515
  24. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement — therapy long-term follow-up of a Swedish cohort. Int J Cancer. 1996;67(3):327-332. https://doi.org/10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T "> 3.0.CO;2-T" target="_blank">https://doi.org/10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T
  25. Moss EL, Taneja S, Munir F, Kent C, Robinson L, Potdar N, Sarhanis P, McDermott H. Iatrogenic menopause after treatment for cervical cancer. Clin Oncol (R. Coll Radiol). 2016;28(12):766-775.  https://doi.org/10.1016/j.clon.2016.08.016
  26. Vargiu V, Amar ID, Rosati A, Dinoi G, Turco LC, Capozzi VA, Scambia G, Villa P. Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric. 2021;24(2):120-127.  https://doi.org/10.1080/13697137.2020.1826426
  27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.  https://doi.org/10.3322/caac.20006
  28. Madsen BS, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M. Risk factors for invasive squamous cell carcinoma of the vulva and vagina — population-based case-control study in Denmark. Int J Cancer. 2008;122(12):2827-2834. https://doi.org/10.1002/ijc.23446
  29. Sherman KJ, Daling JR, McKnight B, Chu J. Hormonal factors in vulvar cancer. A case-control study. J Reprod Med. 1994;39(11):857-861. 
  30. Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer. 1998;83(5):1033-1040.
  31. Melnick S, Cole P, Anderson D, Herbst A. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med. 1987;316(9):514-516.  https://doi.org/10.1056/NEJM198702263160905
  32. Baker DP. Estrogen-replacement therapy in patients with previous endometrial carcinoma. Compr Ther. 1990;16(1):28-35. 
  33. Byrant GW. Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J. 1990;83(6):725-726. 
  34. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol. 1996;175(5):1195-1200. https://doi.org/10.1016/s0002-9378(96)70027-3
  35. Creasman WT, Henderson D, Hinshaw W, Clarke‐Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986;67(3):326-330. 
  36. Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol. 2001;97(4):555-560.  https://doi.org/10.1016/s0029-7844(00)01221-7
  37. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Uterine neoplasms. Version 1.2022 — November 4, 2021.
  38. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol. 1990;36(2):189-191.  https://doi.org/10.1016/0090-8258(90)90171-g
  39. Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer. 2006;16(2):805-808. 
  40. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1739-1748. https://doi.org/10.1001/jama.290.13.1739
  41. Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer. 2014;50(9):1628-1637. https://doi.org/10.1016/j.ejca.2014.03.006
  42. Angiolia R, Luveroa D, Armentob G, Capriglionea S, Capriglione S, Plotti F, Scaletta G, Lopez S, Montera R, Gatti A, et al. Hormone replacement therapy in cancer survivors: utopia? Crit Rev Oncol Hematol. 2018;124:51-60.  https://doi.org/10.1016/j.critrevonc.2018.02.005
  43. Biliatis I, Thomakos N, Rodolakis A, Akrivos N, Zacharakis D, Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. J Obstet Gynaecol. 2012;32(4):321-325.  https://doi.org/10.3109/01443615.2012.668579
  44. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006;24(9):1409-1414. https://doi.org/10.1200/JCO.2005.04.7324
  45. Gadducci A, Zannoni GF. Uterine smooth muscle tumors of unknown malignant potential: a challenging question. Gynecol Oncol. 2019;154(3):631-637.  https://doi.org/10.1016/j.ygyno.2019.07.002
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.